Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-002269-35-IT
EUCTR2005-002269-35-IT
Active, not recruiting
Not Applicable

Phase II trial to evaluate the combination of FOLFOX6 + Bevacizumab in initially unresectable liver metastases from colorectal cancer

AZIENDA OSPEDALIERA POLICLINICO DI MODENA0 sitesAugust 7, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMETASTHATIC COLON-RECTUM AND KIDNEY CANCERMedDRA version: 9.1Level: LLTClassification code 10055114Term: Colon cancer metastatic
DrugsbevacizumabELOXATIN*IV 1FL POLV 100MGFLUOROURACILE TEVA*IV 5FL250MGLEVOFOLENE*EV 1FL 175MG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
METASTHATIC COLON-RECTUM AND KIDNEY CANCER
Sponsor
AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 7, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA POLICLINICO DI MODENA

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Essai de phase II évaluant l'association de FOLFOX et CETUXIMAB avec radiothérapie concomitante en traitement des cancers de l'oesophage de stade III - ERAFOXCarcinome epidermoïde ou glandulaire de l'oesophage de satde III histologiquement prouvé. Tumeurs du cardia à développement oesophagien acceptéesMedDRA version: 8.1Level: PTClassification code 10030151Term: cancer oesophage
EUCTR2006-005550-72-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Active, not recruiting
Phase 1
Trial with immunotherapie for patients with locally advanced head and neck cancerON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCCMedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003175-22-DECharite Universitätsmedizin Berlin66
Active, not recruiting
Phase 1
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112
Active, not recruiting
Not Applicable
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumour
EUCTR2006-006515-76-GBOncolytics Biotech Inc
Recruiting
Not Applicable
Translational Research of Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD)Colorectal Cancer
JPRN-UMIN000028678MCSGO: Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group40